Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Neuro-Oncology
Neuro-Oncology
This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.
Neuro-Oncology
III
Merrell, Ryan
NCT03776071
VICCNEU2124
